FIELD: medicine.
SUBSTANCE: present invention refers to medicine, namely to neurology, and concerns treating sleep disorders. That is ensured by administering an orexin receptor antagonist of formula (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide in a dosage form for oral administration, additionally containing lactose and hydroxypropyl cellulose with low degree of substitution. Administration of this preparation in a daily dose of 2.5 to 10 mg provides achieving average Cmax from 3.0 ng/ml to 7.2 ng/ml for each 1 mg of the active compound.
EFFECT: such mode of administration provides effective treatment of sleep disorders, including achievement of stable balance between easy onset of sleep and prevention of residual sleepiness.
15 cl, 3 dwg, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ESLICARBAZEPINE ACETATE AND METHODS FOR APPLYING THEREOF | 2005 |
|
RU2417085C2 |
| METHODS OF TREATING SJOGREN SYNDROME USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2824354C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| MODULATION OF SYSTEMIC EFFECT OF RIFAXIMIN | 2010 |
|
RU2571268C2 |
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING MINERALOCORTICOID RECEPTOR ANTAGONIST, AND APPLICATION THEREOF | 2017 |
|
RU2725153C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTAGONIST OF MINERALOCORTICOID RECEPTORS AND ITS APPLICATION | 2017 |
|
RU2750667C2 |
| COMPOSITIONS CONTAINING 15-HEPE, AND METHODS OF USING THEM | 2016 |
|
RU2737089C2 |
| APPLICATION OF 4-AMINOPYRIDINE FOR IMPROVING CONDITION IN CASE OF NEUROCOGNITIVE AND/OR NEUROPSYCHIATRIC DISORDER IN PATIENTS WITH DEMYELINATING AND OTHER DISEASES OF NERVOUS SYSTEM | 2010 |
|
RU2563821C2 |
